bluuebunny/crossref_metadata_2025_split huggingface dataset:
Distributed type‐2 fuzzy adaptive control for heterogeneous nonlinear multiagent systems
Authors: Qin Bo , Fan Yongqing , Xiao Tiantian , Li Zhen 
Published: May 2021

AbstractA novel type‐2 fuzzy adaptive consensus control is studied for a class of heterogeneous multiagent systems with identical or nonidentical dimensions. At first, the similar composite structure for a class of heterogeneous multiagent systems with identical or nonidentical dimensions is introduced. Some similar parameters among each agent are defined that can be obtained by calculating the proposed similar properties. Second, according to the graph theory and Lyapunov stability, a novel distributed type‐2 fuzzy adaptive control with similar parameters is constructed for the consensus of nonlinear heterogeneous multiagents with different dimensions, in which all signals can converge to small zero fields. Finally, two simulation examples are addressed for the considered systems to show the effectiveness of the control scheme, and some merits of the control approach are also demonstrated by comparison of similar control.
Validation of the Finnish version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) and evaluation of the applicability of the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) and the Fatigue Scale for Motor and Cognitive Functions (FSMC)
Authors: Hämäläinen Päivi , Leo Vera , Therman Sebastian , Ruutiainen Juhani 
Published: May 2021

AbstractObjectivesCognitive impairment is frequent in multiple sclerosis (MS) as approximately half of the patients manifest some degree of cognitive impairment. The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) has been designed for brief cognitive evaluation. The purpose of the study was to validate the BICAMS along with the Finnish versions of one self‐rating questionnaire each for cognition and fatigue.MethodsA total of 65 MS patients and 45 healthy controls (HC) were assessed with the BICAMS, the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ), and the Fatigue Scale for Motor and Cognitive Functions (FSMC) twice, approximately within nine days.ResultsMS patients scored markedly lower than the HCs on each of the three tests of the BICAMS. Of the patients, 60% scored at least 1.5 SD below the mean of the HCs on at least one test; 49% on the SDMT, 26% on the CVLT‐II, and 28% on the BVMT‐R. Correlation coefficients for the repeated measurement were between 0.75 and 0.89 for the three tests in the whole study sample. MS patients reported more cognitive symptoms and more fatigue than the HCs. Cronbach's alpha was 0.94 for the MSNQ and 0.98 for the FSMC. Correlation coefficient for the repeated measurement was 0.91 for the MSNQ and between 0.92 and 0.94 for the FSMC scores for the whole study sample.ConclusionsThe present study supports the validity of the Finnish version of the BICAMS. The SDMT was the most sensitive of the three BICAMS tests and showed cognitive impairment in half of the patients. The Finnish versions of the MSNQ and the FSMC proved useful tools in approaching concerns related to cognition and fatigue.
The Delta Study – Prevalence and characteristics of mood disorders in 924 individuals with low mood: Results of the of the World Health Organization Composite International Diagnostic Interview (CIDI)
Authors: Martin‐Key Nayra A. , Olmert Tony , Barton‐Owen Giles , Han Sung Yeon Sarah , Cooper Jason D. , Eljasz Pawel , Farrag Lynn P. , Friend Lauren V. , Bell Emily , Cowell Dan , Tomasik Jakub , Bahn Sabine 
Published: May 2021

AbstractObjectivesThe Delta Study was undertaken to improve the diagnosis of mood disorders in individuals presenting with low mood. The current study aimed to estimate the prevalence and explore the characteristics of mood disorders in participants of the Delta Study, and discuss their implications for clinical practice.MethodsIndividuals with low mood (Patients Health Questionnaire‐9 score ≥5) and either no previous mood disorder diagnosis (baseline low mood group, n = 429), a recent (≤5 years) clinical diagnosis of MDD (baseline MDD group, n = 441) or a previous clinical diagnosis of BD (established BD group, n = 54), were recruited online. Self‐reported demographic and clinical data were collected through an extensive online mental health questionnaire and mood disorder diagnoses were determined with the World Health Organization Composite International Diagnostic Interview (CIDI).ResultsThe prevalence of BD and MDD in the baseline low mood group was 24% and 36%, respectively. The prevalence of BD among individuals with a recent diagnosis of MDD was 31%. Participants with BD in both baseline low mood and baseline MDD groups were characterized by a younger age at onset of the first low mood episode, more severe depressive symptoms and lower wellbeing, relative to the MDD or low mood groups. Approximately half the individuals with BD diagnosed as MDD (49%) had experienced (hypo)manic symptoms prior to being diagnosed with MDD.ConclusionsThe current results confirm high under‐ and misdiagnosis rates of mood disorders in individuals presenting with low mood, potentially leading to worsening of symptoms and decreased well‐being, and indicate the need for improved mental health triage in primary care.
Crude probability of death for cancer patients by spread of disease in New South Wales, Australia 1985 to 2014
Authors: Yu Xue Qin , Dasgupta Paramita , Kahn Clare , Kou Kou , Cramb Susanna , Baade Peter 
Published: May 2021

AbstractBackgroundTo estimate trends in the crude probability of death for cancer patients by sex, age and spread of disease over the past 30 years in New South Wales, Australia.MethodsPopulation‐based cohort of 716,501 people aged 15–89 years diagnosed with a first primary cancer during 1985–2014 were followed up to 31 December 2015. Flexible parametric relative survival models were used to estimate the age‐specific crude probability of dying from cancer and other causes by calendar year, sex and spread of disease for all solid tumours combined and cancers of the colorectum, lung, female breast, prostate and melanoma.ResultsEstimated 10‐year sex, age and spread‐specific crude probabilities of cancer death generally decreased over time for most cancer types, although the magnitude of the decrease varied. For example, out of 100 fifty‐year old men with localized prostate cancer, 12 would have died from their cancer if diagnosed in 1985 and 3 in 2014. Greater degree of spread was consistently associated with higher probability of dying from cancer, although outcomes for lung cancer were consistently poor. For both males and females, the probability of non‐cancer deaths was higher among older patients, those diagnosed with localized cancers and where cancer survival was higher.ConclusionCrude probabilities presented here may be useful in helping clinicians and their patients better understand prognoses and make informed decisions about treatment. They also provide novel insights into the relative contributions that early detection and improved treatments have on the observed temporal patterns in cancer survival.
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
Authors: Jones Robin L. , Herzog Thomas J. , Patel Shreyaskumar R. , von Mehren Margaret , Schuetze Scott M. , Van Tine Brian A. , Coleman Robert L. , Knoblauch Roland , Triantos Spyros , Hu Peter , Shalaby Waleed , McGowan Tracy , Monk Bradley J. , Demetri George D. 
Published: May 2021

AbstractBackgroundAs with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are still limited. Cardiac safety for trabectedin monotherapy (T) for STS or in combination with pegylated liposomal doxorubicin (T+PLD) for ROC was evaluated in this retrospective postmarketing regulatory commitment.MethodsPatient data for multiple cardiac‐related treatment‐emergent adverse events (cTEAEs) were evaluated in pooled analyses of ten phase 2 trials, one phase 3 trial in STS (n = 982), and two phase 3 trials in ROC (n = 1231).ResultsMultivariate analyses on pooled trabectedin data revealed that cardiovascular medical history (risk ratio [RR (95% CI)]: 1.90 [1.24‐2.91]; p = 0.003) and age ≥65 years (RR [95% CI]: 1.78 [1.12‐2.83]; p = 0.014) were associated with increased risk for cTEAEs. Multivariate analyses showed increased risk of experiencing cTEAEs with T+PLD compared to PLD monotherapy (RR [95% CI]: 2.70 [1.75‐4.17]; p < 0.0001) and with history of prior cardiac medication (RR [95% CI]: 1.88 [1.16‐3.05]; p = 0.010).ConclusionsFor patients with STS or ROC who still have limited treatment options, trabectedin may be initiated after carefully considering benefit versus risk.Trial Registration (ClinicalTrials.gov): NCT01343277; NCT00113607; NCT01846611.
Competing‐risks nomograms for predicting cause‐specific mortality in parotid‐gland carcinoma: A population‐based analysis
Authors: Xu Fengshuo , Feng Xiaojie , Zhao Fanfan , Huang Qiao , Han Didi , Li Chengzhuo , Zheng Shuai , Lyu Jun 
Published: May 2021

AbstractIntroductionParotid‐gland carcinoma (PGC) is a relatively rare tumor that comprises a group of heterogeneous histologic subtypes. We used the Surveillance, Epidemiology, and End Results (SEER) program database to apply a competing‐risks analysis to PGC patients, and then established and validated predictive nomograms for PGC.MethodsSpecific screening criteria were applied to identify PGC patients and extract their clinical and other characteristics from the SEER database. We used the cumulative incidence function to estimate the cumulative incidence rates of PGC‐specific death (GCD) and other cause‐specific death (OCD), and tested for differences between groups using Gray's test. We then identified independent prognostic factors by applying the Fine–Gray proportional subdistribution hazard approach, and constructed predictive nomograms based on the results. Calibration curves and the concordance index (C‐index) were employed to validate the nomograms.ResultsWe finally identified 4,075 eligible PGC patients who had been added to the SEER database from 2004 to 2015. Their 1‐, 3‐, and 5‐year cumulative incidence rates of GCD were 10.1%, 21.6%, and 25.7%, respectively, while those of OCD were 2.9%, 6.6%, and 9.0%. Age, race, World Health Organization histologic risk classification, differentiation grade, American Joint Committee on Cancer (AJCC) T stage, AJCC N stage, AJCC M stage, and RS (radiotherapy and surgery status) were independent predictors of GCD, while those of OCD were age, sex, marital status, AJCC T stage, AJCC M stage, and RS. These factors were integrated for constructing predictive nomograms. The results for calibration curves and the C‐index suggested that the nomograms were well calibrated and had good discrimination ability.ConclusionWe have used the SEER database to establish—to the best of our knowledge—the first competing‐risks nomograms for predicting the 1‐, 3‐, and 5‐year cause‐specific mortality in PGC. The nomograms showed relatively good performance and can be used in clinical practice to assist clinicians in individualized treatment decision‐making.
Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib
Authors: Qin Boyu , Xin Lingli , Hou Qingxiang , Yang Bo , Zhang Jing , Qi Xiaoguang , Wei Yingtian , Hu Yi , Xiong Qi 
Published: May 2021

AbstractBackgroundAnlotinib significantly extended progression‐free survival (PFS) and overall survival (OS) in small‐cell lung cancer (SCLC) as third or later line treatment.MethodsIn this study, we retrospectively analyzed the efficacy and safety of anlotinib in the clinical practice and aimed to identify risk factors for predicting the clinical benefit of anlotinib in SCLC patients. 29 SCLC patients treated with anlotinib monotherapy or combination therapy as second or later line treatment were included. PFS, OS, objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed.ResultsIn whole patients, the median PFS was 2.1 months (95% confidence interval (CI): 1.1–3.2 months); The ORR and DCR were 10.3% and 48.3%, respectively; The median OS was 7.2 months (95%CI: 3.2–11.2 months). Cox regression analysis demonstrated that response to first‐line treatment was the independent risk factor for PFS. The ORR (20.0% vs. 0%) and DCR (53.3% vs. 42.9%) were promoted in patients treated with anlotinib combination therapy comparing to anlotinib monotherapy. The most common AEs were hoarseness, fatigue, decreased appetite, oral mucositis, and anemia. No treatment‐related AEs graded 3 or more.ConclusionAnlotinib is an effective option for SCLC patients with tolerable toxicity as second or later line treatment. Patients sensitive to first‐line treatment had longer PFS when treated with anlotinib. Anloitnib combined with other therapy increased the efficacy without adding toxicity.
Challenges to identity integration amongst sexual minority British Muslim South Asian men
Authors: Mitha Karim , Ali Sheila , Koc Yasin 
Published: May 2021

AbstractSince the Stonewall uprisings, there has been greater social acceptance of homosexuality within Western contexts. Nevertheless, those who are at the intersection of more than one minority identity continue to face prejudice and discrimination, including homophobia and racism. Though there has been increasing work regarding the experiences of sexual minority people of colour (POC), a lacuna remains regarding the experiences of sexual minority British Muslim South Asian men and the integration of sexual minority and religious identities, particularly within a context of increased societal acceptance towards sexual minorities and societal Islamophobia. In this study, 38 sexual minority British Muslim South Asian men were recruited via snowball sampling and interviewed. Data were examined via reflexive thematic analysis. Five themes were identified: degrees of “outness”, hegemonic Whiteness and the LGBTQ+ community, internalisation of White hegemony, distancing from the sexual minority religio‐cultural ingroup, and attempting to reconcile potential identity conflict between sexual orientation identity and religious and cultural identities. Respondents' experiences highlighted substantial social exclusion due to intersectional disadvantage as well as a lack of intra‐community social support, suggesting substantial isolation, psychological implications and a general eschewing of identity affiliation based on sexual attraction. This has implications on services predicated on identity affiliation which may potentially exclude the needs of hidden and intersectionally disadvantaged populations.
Bosutinib‐associated interstitial lung disease and pleural effusion: A case report and literature review
Authors: Liu Qiuying (Selina) , Ass'ad Nour Ali , Arana Yi Cecilia 
Published: May 2021

AbstractBosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.
Transcatheter management of adult aortic coarctation with “Railway” technique
Authors: Yuan Xun , Mitsis Andreas , Rigby Michael , Nienaber Christoph A. 
Published: May 2021

AbstractEndografting for atretic coarctation is technically feasible to avoid the risks of open surgery. It requires a strategic and structured endovascular approach such as the “Railway” technique for safe and successful restructuring of complete aortic atresia and avoiding rupture or bleeding.
An enlarging neck mass with dyspnea and left finger pain in a 63‐year‐old woman
Authors: Hoang Thanh D. , Snitchler Andrea N. , Shakir Mohamed K.M. 
Published: May 2021

AbstractWe described a rare presentation of papillary thyroid cancer metastasized to left finger. This case highlights the importance of an early and effective engagement of multidisciplinary team approach to optimize patient care and that papillary thyroid cancer can occasionally pursue an aggressive, lethal course.
Minimally invasive mitral valve repair and ablation of concomitant atrial fibrillation in a patient with severe hemophilia A
Authors: Bogachev‐Prokophiev Alexander , Sharifulin Ravil , Karadzha Anastasiia , Larionova Natalya , Shmyrev Vladimir , Kornilov Igor , Mamaev Andrey , Afanasyev Alexander , Pivkin Alexey 
Published: May 2021

AbstractMinimally invasive mitral valve repair and ablation of atrial fibrillation, combined with FVIII level‐controlled replacement therapy, can be safely performed in patients with severe hemophilia.
Neurobrucellosis: A differential not to be missed in patients presenting with neuropsychiatric features
Authors: Nepal Gaurav , Balayar Ramesh , Bhatta Suraj , Acharya Sulav , Gajurel Bikram Prasad , Karn Ragesh , Rajbhandari Reema , Paudel Sunanda , Gautam Niraj , Shrestha Ashish , Ojha Rajeev 
Published: May 2021

AbstractWhen a patient presents with undulating fever and neuropsychiatric features, neurobrucellosis should be considered as a differential diagnosis. If diagnosed early, neurobrucellosis is a treatable disease with a favorable outcome.
Thermodynamic Assessment of Chemical Equilibrium for the Synthesis of Solketal in the Liquid Phase
Authors: Perez Federico M. , Nichio Nora , Pompeo Francisco 
Published: May 2021

AbstractThe synthesis of solketal is one of the innovative routes of glycerol valorization to value‐added products, and the simulation of the process requires the knowledge of thermodynamic properties that are not still available in the literature. In this work, the specific heat capacity as a function of temperature and the enthalpy and entropy of formation of all compounds involved in the reaction were calculated by employing a second‐order group‐additivity method. Expressions for the enthalpy of reaction and equilibrium constant as a function of temperature were also obtained. The glycerol conversion at equilibrium was calculated at different temperatures, pressures, acetone/glycerol molar ratios, and initial water contents, considering the nonideality of the liquid phase.
Mechanistic Study of the Activation and the Electrocatalytic Reduction of Hydrogen Peroxide by Cu‐tmpa in Neutral Aqueous Solution
Authors: Langerman Michiel , Hetterscheid Dennis G. H. 
Published: May 2021

AbstractHydrogen peroxide plays an important role as an intermediate and product in the reduction of dioxygen by copper enzymes and mononuclear copper complexes. The copper(II) tris(2‐pyridylmethyl)amine complex (Cu‐tmpa) has been shown to produce H2O2 as an intermediate during the electrochemical 4‐electron reduction of O2. We investigated the electrochemical hydrogen peroxide reduction reaction (HPRR) by Cu‐tmpa in a neutral aqueous solution. The catalytic rate constant of the reaction was shown to be one order of magnitude lower than the reduction of dioxygen. A significant solvent kinetic isotope effect (KIE) of 1.4 to 1.7 was determined for the reduction of H2O2, pointing to a Fenton‐like reaction pathway as the likely catalytic mechanism, involving a single copper site that produces an intermediate copper(II) hydroxo species and a free hydroxyl radical anion in the process.
Machine learning in prediction of intrinsic aqueous solubility of drug‐like compounds: Generalization, complexity, or predictive ability?
Authors: Lovrić Mario , Pavlović Kristina , Žuvela Petar , Spataru Adrian , Lučić Bono , Kern Roman , Wong Ming Wah 
Published: May 2021

AbstractWe present a collection of publicly available intrinsic aqueous solubility data of 829 drug‐like compounds. Four different machine learning algorithms (random forests [RF], LightGBM, partial least squares, and least absolute shrinkage and selection operator [LASSO]) coupled with multistage permutation importance for feature selection and Bayesian hyperparameter optimization were used for the prediction of solubility based on chemical structural information. Our results show that LASSO yielded the best predictive ability on an external test set with a root mean square error (RMSE) (test) of 0.70 log points, anR2(test) of 0.80, and 105 features. Taking into account the number of descriptors as well, an RF model achieves the best balance between complexity and predictive ability with an RMSE(test) of 0.72 log points, anR2(test) of 0.78, and with only 17 features. On a more aggressive test set (principal component analysis [PCA]‐based split), better generalization was observed for the RF model. We propose a ranking score for choosing the best model, as test set performance is only one of the factors in creating an applicable model. The ranking score is a weighted combination of generalization, number of features, and test performance. Out of the two best learners, a consensus model was built exhibiting the best predictive ability and generalization with RMSE(test) of 0.67 log points and aR2(test) of 0.81.
A review of halide charge carriers for rocking‐chair and dual‐ion batteries
Authors: Sandstrom Sean K. , Chen Xin , Ji Xiulei 
Published: May 2021

AbstractThis review discusses how halide ion species have been used as charge carriers in both anion rocking‐chair and dual‐ion battery (DIB) systems. The anion rocking‐chair batteries based on fluoride and chloride have emerged over the past decade and are garnering increased research interest due to their large theoretical energy density values and the natural abundance of halide‐containing materials. Moreover, DIBs that use halide species as their anionic charge carrier are seen as one of the promising next‐generation battery technologies due to their low cost and high working potentials. Although numerous polyatomic anions have been studied as charge carriers, the use of single halide ions (i.e., F− and Cl−) and metal‐based superhalides (e.g., [MgCl3]−) as anionic charge carriers in DIBs has been considerably less explored. Herein, we provide an overview of some of the key advances and recent progress that has been made with regard to halide ion charge carriers in electrochemical energy storage. We offer our perspectives on the current state of the field and provide a roadmap in hopes that it helps researchers toward making new advances in these promising and emerging areas.
Malignant transformation of salivary gland pleomorphic adenoma: proof of principle
Authors: Valstar Matthijs H , Mast Hetty , ten Hove Ivo , Moonen Laura R , Balm Alfons JM , Smeele Ludi E , Koljenović Senada , Dinjens Winand NM , van Velthuysen Marie‐Louise F 
Published: May 2021

AbstractSupposed risk of malignant transformation of salivary gland pleomorphic adenoma (SGPA) is an important reason for aggressive retreatment in recurrent pleomorphic adenoma (RPA). However, although the diagnostic category ‘carcinoma ex‐pleomorphic adenoma’ suggests that malignant transformation of a pleomorphic adenoma is a regular event, this has to date not been shown to occur in sequential lesions of one patient. Here, we show the molecular events in transformation to malignancy of a pleomorphic adenoma of the parotid gland. Detailed molecular analysis revealed an LIFR/PLAG1 translocation characteristic for pleomorphic adenoma and, next to this, a PIK3R1 frameshift mutation and several allelic imbalances. In subsequent malignant recurrences, the same LIFR/PLAG1 translocation, PIK3R1 frameshift mutation, and allelic imbalances were present in addition to TP53 mutations. Thus, this case not only shows malignant transformation of SGPA, but also demonstrates that molecular analysis can be of help in recognising malignancy in the rare instance of RPA.